Treatment of Advanced Non-Small Cell Lung Cancer in the Elderly

Lecia V. Sequist; Panos Fidias

doi:10.1055/s-2005-871987

Seminars in Respiratory and Critical Care Medicine, Inhaltsverzeichnis

Semin Respir Crit Care Med 2005; 26(3): 289-297
DOI: 10.1055/s-2005-871987

Treatment of Advanced Non-Small Cell Lung Cancer in the Elderly

Lecia V. Sequist¹ , Panos Fidias¹

¹Center for Thoracic Cancers, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts

Abstract

ABSTRACT

Non-small cell lung cancer (NSCLC) is primarily a disease of the elderly. Although NSCLC is the leading cause of cancer death in the United States and the overall prognosis of this disease is poor, treatment improves survival compared with best supportive care, independent of the stage of disease. Elderly patients have a particularly poor prognosis with NSCLC compared with younger patients, likely due to age-related biases in referral and treatment patterns. There is an emerging literature regarding the tolerability of NSCLC treatments in elderly patients. In advanced disease, subgroup analyses of the elderly population participating in randomized clinical trials as well as elder-specific prospective randomized trials have demonstrated that elderly NSCLC patients derive equivalent survival benefit from the treatment of NSCLC as younger patients. This treatment is tolerable for “fit” elderly patients, and modified regimens are available for the more frail elderly patients. Evaluating the relative fitness of an elderly patient may be achieved through an assessment of functional ability. As the U.S. population ages and the incidence of NSCLC rises, an understanding of treatment options for elderly patients with NSCLC is vital for all clinicians involved in their clinical care.

KEYWORDS

Non-small cell lung cancer - elderly - comprehensive geriatric assessment

Volltext

Referenzen

REFERENCES

1 US Census Bureau .US interim projections by age, race, sex and Hispanic origin. Available at: http://www.census.gov/ipc/www/usinterimproj/. Accessed January 25, 2005.
2 American Cancer Society .Cancer Statistics 2005 Presentation. Available at: http://www.cancer.org/docroot/PRO/content/PRO_1_1_Cancer_Statistics_2005_Presentation.asp. Accessed January 25, 2005.
3 Yancik R. Cancer burden in the aged: an epidemiologic and demographic overview. Cancer. 1997; 80 1273-1283
4 Hurria A, Kris M G. Management of lung cancer in older adults. CA Cancer J Clin. 2003; 53 325-341
5 Brundage M D, Davies D, Mackillop W J. Prognostic factors in non-small cell lung cancer: a decade of progress. Chest. 2002; 122 1037-1057
6 Wertzel H, Siebert H, Lange W, Swoboda L, Graf E, Hasse J. Results after surgery in stage-I bronchogenic carcinoma. Thorac Cardiovasc Surg. 1998; 46 365-369
7 Diez M, Torres A, Maestro M L et al.. Prediction of survival and recurrence by serum and cytosolic levels of CEA, CA125 and SCC antigens in resectable non-small-cell lung cancer. Br J Cancer. 1996; 73 1248-1254
8 Mori M, Kohli A, Baker S P, Savas L, Fraire A E. Laminin and cathepsin B as prognostic factors in stage I non-small cell lung cancer: are they useful?. Mod Pathol. 1997; 10 572-577
9 Fontanini G, Lucchi M, Vignati S et al.. Angiogenesis as a prognostic indicator of survival in non-small-cell lung carcinoma: a prospective study. J Natl Cancer Inst. 1997; 89 881-886
10 Mountain C F. Revisions in the International System for Staging Lung Cancer. Chest. 1997; 111 1710-1717
11 O’Rourke M A, Feussner J R, Feigl P, Laszlo J. Age trends of lung cancer stage at diagnosis: implications for lung cancer screening in the elderly. JAMA. 1987; 258 921-926
12 Nugent W C, Edney M T, Hammerness P G, Dain B J, Maurer L H, Rigas J R. Non-small cell lung cancer at the extremes of age: impact on diagnosis and treatment. Ann Thorac Surg. 1997; 63 193-197
13 Spira A, Ettinger D S. Multidisciplinary management of lung cancer. N Engl J Med. 2004; 350 379-392
14 Bunn Jr P A. Chemotherapy for advanced non-small-cell lung cancer: who, what, when, why?. J Clin Oncol. 2002; 20(18 Suppl) 23S-33S
15 Townsley C A, Naidoo K, Pond G R, Melnick W, Straus S E, Siu L L. Are older cancer patients being referred to oncologists? A mail questionnaire of Ontario primary care practitioners to evaluate their referral patterns. J Clin Oncol. 2003; 21 4627-4635
16 Yellen S B, Cella D F, Leslie W T. Age and clinical decision making in oncology patients. J Natl Cancer Inst. 1994; 86 1766-1770
17 Silvestri G, Pritchard R, Welch H G. Preferences for chemotherapy in patients with advanced non-small cell lung cancer: descriptive study based on scripted interviews. BMJ. 1998; 317 771-775
18 Smith T J, Penberthy L, Desch C E et al.. Differences in initial treatment patterns and outcomes of lung cancer in the elderly. Lung Cancer. 1995; 13 235-252
19 Dillman R O, Seagren S L, Propert K J et al.. A randomized trial of induction chemotherapy plus high-dose radiation versus radiation alone in stage III non-small-cell lung cancer. N Engl J Med. 1990; 323 940-945
20 Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Non-small Cell Lung Cancer Collaborative Group. BMJ. 1995; 311 899-909
21 Movsas B, Moughan J, Komaki R et al.. Radiotherapy patterns of care study in lung carcinoma. J Clin Oncol. 2003; 21 4553-4559
22 Earle C C, Neumann P J, Gelber R D, Weinstein M C, Weeks J C. Impact of referral patterns on the use of chemotherapy for lung cancer. J Clin Oncol. 2002; 20 1786-1792
23 Hillner B E, McDonald M K, Desch C E, Smith T J, Penberthy L T, Retchin S M. A comparison of patterns of care of nonsmall cell lung carcinoma patients in a younger and Medigap commercially insured cohort. Cancer. 1998; 83 1930-1937
24 Finkelstein D M, Ettinger D S, Ruckdeschel J C. Long-term survivors in metastatic non-small-cell lung cancer: an Eastern Cooperative Oncology Group Study. J Clin Oncol. 1986; 4 702-709
25 Stanley K E. Prognostic factors for survival in patients with inoperable lung cancer. J Natl Cancer Inst. 1980; 65 25-32
26 Socinski M A, Zhang C, Herndon II J E et al.. Combined modality trials of the Cancer and Leukemia Group B in stage III non-small-cell lung cancer: analysis of factors influencing survival and toxicity. Ann Oncol. 2004; 15 1033-1041
27 Albain K S, Crowley J J, LeBlanc M, Livingston R B. Survival determinants in extensive-stage non-small-cell lung cancer: the Southwest Oncology Group experience. J Clin Oncol. 1991; 9 1618-1626
28 Hutchins L F, Unger J M, Crowley J J, Coltman Jr C A, Albain K S. Underrepresentation of patients 65 years of age or older in cancer-treatment trials. N Engl J Med. 1999; 341 2061-2067
29 Murthy V H, Krumholz H M, Gross C P. Participation in cancer clinical trials: race-, sex-, and age-based disparities. JAMA. 2004; 291 2720-2726
30 Lewis J H, Kilgore M L, Goldman D P et al.. Participation of patients 65 years of age or older in cancer clinical trials. J Clin Oncol. 2003; 21 1383-1389
31 Yee K W, Pater J L, Pho L, Zee B, Siu L L. Enrollment of older patients in cancer treatment trials in Canada: why is age a barrier?. J Clin Oncol. 2003; 21 1618-1623
32 Weinmann M, Jeremic B, Toomes H, Friedel G, Bamberg M. Treatment of lung cancer in the elderly, I: Non-small cell lung cancer. Lung Cancer. 2003; 39 233-253
33 Pagni S, Federico J A, Ponn R B. Pulmonary resection for lung cancer in octogenarians. Ann Thorac Surg. 1997; 63 785-789
34 Yamamoto K, Padilla Alarcon J, Calvo Medina V et al.. Surgical results of stage I non-small cell lung cancer: comparison between elderly and younger patients. Eur J Cardiothorac Surg. 2003; 23 21-25
35 Dyszkiewicz W, Pawlak K, Gasiorowski L. Early post-pneumonectomy complications in the elderly. Eur J Cardiothorac Surg. 2000; 17 246-250
36 van Rens M T, de la Riviere A B, Elbers H R, van Den Bosch J M. Prognostic assessment of 2,361 patients who underwent pulmonary resection for non-small cell lung cancer, stage I, II, and IIIA. Chest. 2000; 117 374-379
37 Jazieh A R, Hussain M, Howington J A et al.. Prognostic factors in patients with surgically resected stages I and II non-small cell lung cancer. Ann Thorac Surg. 2000; 70 1168-1171
38 Bach P B, Cramer L D, Schrag D, Downey R J, Gelfand S E, Begg C B. The influence of hospital volume on survival after resection for lung cancer. N Engl J Med. 2001; 345 181-188
39 Pignon T, Gregor A, Schaake Koning C, Roussel A, Van Glabbeke M, Scalliet P. Age has no impact on acute and late toxicity of curative thoracic radiotherapy. Radiother Oncol. 1998; 46 239-248
40 Singh A K, Lockett M A, Bradley J D. Predictors of radiation-induced esophageal toxicity in patients with non-small-cell lung cancer treated with three-dimensional conformal radiotherapy. Int J Radiat Oncol Biol Physiol. 2003; 55 337-341
41 Schild S E, Stella P J, Geyer S M et al.. The outcome of combined-modality therapy for stage III non-small-cell lung cancer in the elderly. J Clin Oncol. 2003; 21 3201-3206
42 Rocha Lima C M, Herndon II J E, Kosty M, Clamon G, Green M R. Therapy choices among older patients with lung carcinoma: an evaluation of two trials of the Cancer and Leukemia Group B. Cancer. 2002; 94 181-187
43 Langer C J, Hsu C, Curran W J et al.. Elderly patients (pts) with locally advanced non-small cell lung cancer (LA-NSCLC) benefit from combined modality therapy: secondary analysis of Radiation Therapy Oncology Group (RTOG) 94-10. Paper presented at: American Society of Clinical Oncology 2002 Orlando, FL; Abstract 1193
44 Brundage M D, Davidson J R, Mackillop W J. Trading treatment toxicity for survival in locally advanced non-small cell lung cancer. J Clin Oncol. 1997; 15 330-340
45 Fried T R, Bradley E H, Towle V R, Allore H. Understanding the treatment preferences of seriously ill patients. N Engl J Med. 2002; 346 1061-1066
46 Pfister D G, Johnson D H, Azzoli C G et al.. American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003. J Clin Oncol. 2004; 22 330-353
47 Rapp E, Pater J L, Willan A et al.. Chemotherapy can prolong survival in patients with advanced non-small-cell lung cancer: report of a Canadian multicenter randomized trial. J Clin Oncol. 1988; 6 633-641
48 Cullen M H, Billingham L J, Woodroffe C M et al.. Mitomycin, ifosfamide, and cisplatin in unresectable non-small-cell lung cancer: effects on survival and quality of life. J Clin Oncol. 1999; 17 3188-3194
49 Stephens R J, Fairlamb D, Gower N H et al.. The Big Lung Trial (BLT): determining the value of cisplatin-based chemotherapy for all patients with non-small cell lung cancer (NSCLC). Preliminary results in the supportive care setting. Paper presented at: American Society of Clinical Oncology 2002 Orlando, FL; Abstract 1161
50 Le Chevalier T, Brisgand D, Douillard J Y et al.. Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: results of a European multicenter trial including 612 patients. J Clin Oncol. 1994; 12 360-367
51 Wozniak A J, Crowley J J, Balcerzak S P et al.. Randomized trial comparing cisplatin with cisplatin plus vinorelbine in the treatment of advanced non-small-cell lung cancer: a Southwest Oncology Group study. J Clin Oncol. 1998; 16 2459-2465
52 Cardenal F, Lopez-Cabrerizo M P, Anton A et al.. Randomized phase III study of gemcitabine-cisplatin versus etoposide-cisplatin in the treatment of locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol. 1999; 17 12-18
53 Bonomi P, Kim K, Fairclough D et al.. Comparison of survival and quality of life in advanced non-small-cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: results of an Eastern Cooperative Oncology Group trial. J Clin Oncol. 2000; 18 623-631
54 Go R S, Adjei A A. Review of the comparative pharmacology and clinical activity of cisplatin and carboplatin. J Clin Oncol. 1999; 17 409-422
55 Schiller J H, Harrington D, Belani C P et al.. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med. 2002; 346 92-98
56 Georgoulias V, Papadakis E, Alexopoulos A et al.. Platinum-based and non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a randomised multicentre trial. Lancet. 2001; 357 1478-1484
57 Kosmidis P, Mylonakis N, Nicolaides C et al.. Paclitaxel plus carboplatin versus gemcitabine plus paclitaxel in advanced non-small-cell lung cancer: a phase III randomized trial. J Clin Oncol. 2002; 20 3578-3585
58 Langer C J, Manola J, Bernardo P et al.. Cisplatin-based therapy for elderly patients with advanced non-small-cell lung cancer: implications of Eastern Cooperative Oncology Group 5592, a randomized trial. J Natl Cancer Inst. 2002; 94 173-181
59 Langer C J, Vangel M, Schiller J H et al.. Age-specific subanalysis of ECOG 1594: fit elderly patients (70-80 yrs) with NSCLC do as well as younger pts (< 70). Paper presented at: American Society of Clinical Oncology 2003 Chicago, IL; Abstract 2571
60 Kelly K, Giarritta S, Akerley W et al.. Should older patients (pts) receive combination chemotherapy for advanced stage non-small cell lung cancer (NSCLC)? An analysis of Southwest Oncology Trials 9509 and 9308. Paper presented at: American Society of Clinical Oncology 2001 San Francisco, CA; Abstract 1313
61 Hensing T A, Peterman A H, Schell M J, Lee J H, Socinski M A. The impact of age on toxicity, response rate, quality of life, and survival in patients with advanced, stage IIIB or IV non-small cell lung carcinoma treated with carboplatin and paclitaxel. Cancer. 2003; 98 779-788
62 Fossella F V, Belani C P. Phase III study (TAX 326) of docetaxel-cisplatin (DC) and docetaxel-carboplatin (DCb) versus vinorelbine-cisplatin (VC) for the first-line treatment of advanced/metastatic non-small-cell lung cancer (NSCLC): Analysis in elderly patients. Paper presented at: American Society of Clinical Oncology 2003 Chicago, IL; Abstract 2528
63 Lilenbaum R C, Herndon II J E, List M A et al.. Single-agent versus combination chemotherapy in advanced non-small-cell lung cancer: the cancer and leukemia group B (study 9730). J Clin Oncol. 2005; 23 190-196
64 Effects of vinorelbine on quality of life and survival of elderly patients with advanced non-small-cell lung cancer. The Elderly Lung Cancer Vinorelbine Italian Study Group. J Natl Cancer Inst. 1999; 91 66-72
65 Gridelli C. The ELVIS trial: a phase III study of single-agent vinorelbine as first-line treatment in elderly patients with advanced non-small cell lung cancer. Elderly Lung Cancer Vinorelbine Italian Study. Oncologist. 2001; 6(Suppl 1) 4-7
66 Frasci G, Lorusso V, Panza N et al.. Gemcitabine plus vinorelbine versus vinorelbine alone in elderly patients with advanced non-small-cell lung cancer. J Clin Oncol. 2000; 18 2529-2536
67 Gridelli C, Perrone F, Gallo C et al.. Chemotherapy for elderly patients with advanced non-small-cell lung cancer: the Multicenter Italian Lung Cancer in the Elderly Study (MILES) phase III randomized trial. J Natl Cancer Inst. 2003; 95 362-372
68 Balducci L, Extermann M. Management of cancer in the older person: a practical approach. Oncologist. 2000; 5 224-237
69 Balducci L, Beghe C. The application of the principles of geriatrics to the management of the older person with cancer. Crit Rev Oncol Hematol. 2000; 35 147-154
70 Stuck A E, Siu A L, Wieland G D, Adams J, Rubenstein L Z. Comprehensive geriatric assessment: a meta-analysis of controlled trials. Lancet. 1993; 342 1032-1036
71 Rich M W, Beckham V, Wittenberg C, Leven C L, Freedland K E, Carney R M. A multidisciplinary intervention to prevent the readmission of elderly patients with congestive heart failure. N Engl J Med. 1995; 333 1190-1195
72 Repetto L, Comandini D. Cancer in the elderly: assessing patients for fitness. Crit Rev Oncol Hematol. 2000; 35 155-160
73 Solomon D, Sue Brown A, Brummel-Smith K et al.. Best paper of the 1980s: National Institutes of Health Consensus Development Conference Statement: geriatric assessment methods for clinical decision-making. 1988. J Am Geriatr Soc. 2003; 51 1490-1494
74 Repetto L, Fratino L, Audisio R A et al.. Comprehensive geriatric assessment adds information to Eastern Cooperative Oncology Group performance status in elderly cancer patients: an Italian Group for Geriatric Oncology Study. J Clin Oncol. 2002; 20 494-502
75 Extermann M. Comprehensive geriatric assessment basics for the cancer professional. J Oncol Manag. 2003; 12 13-17
76 Basso U, Monfardini S. Multidimensional geriatric evaluation in elderly cancer patients: a practical approach. Eur J Cancer Care (Engl). 2004; 13 424-433
77 Zagonel V, Fratino L, Piselli P et al.. The comprehensive geriatric assessment (CGA) predicts mortality among elderly cancer patients (ECP). Paper presented at: American Society of Clinical Oncology 2002 Orlando, FL; Abstract 1458
78 Gillespie T W, Patterson H, Harris W B et al.. Improving clinical outcomes in elderly oncology patients. Paper presented at: American Society of Clinical Oncology 2004 New Orleans, LA; Abstract 6075
79 Ribeiro M J, Patterson H, Shumate M et al.. Compliance with guidelines for elderly patients undergoing cancer therapy. Paper presented at: American Society of Clinical Oncology 2004 New Orleans, LA; Abstract 6148
80 Siegel A B, Fiore J M, Ketas J C et al.. Novel functional assessment techniques for geriatric lymphoma patients. Paper presented at: American Society of Clinical Oncology 2004 New Orleans, LA; Abstract 8166
81 Hurria A, Gupta S, Zauderer M et al.. Development of a comprehensive geriatric assessment (CGA) measure for older patients (pts) with cancer: a feasibility study. Paper presented at: American Society of Clinical Oncology 2004 New Orleans, LA; Abstract 8162
82 Saliba D, Elliott M, Rubenstein L Z et al.. The Vulnerable Elders Survey: a tool for identifying vulnerable older people in the community. J Am Geriatr Soc. 2001; 49 1691-1699

Lecia V SequistM.D.

Massachusetts General Hospital Cancer Center

Yawkey Center for Outpatient Care

32 Fruit St., 7th fl., Boston, MA 02114

eMail: LVSequist@Partners.org